AVPR2 and overactive bladder: The presence of the β3-AR receptor on the same tubular cells expressing AVPR2, together with the availability of synthetic β3-AR agonists such as mirabegron (Betmiga®), the first approved for use in humans for the treatment of an overactive bladder (OAB) [11,13,28,29,30], suggest that mirabegron treatment might be effective in inducing antidiuresis in XNDI patients.